R. Keith Woods has served as Chief Operating Officer of Scholar Rock since April 2025. He has over three decades of experience in the biopharmaceutical industry, having served most recently as Chief Operating Officer of argenx Pharmaceuticals, where he led the company through its transition from an R&D organization to become a fully integrated global biopharmaceutical organization. During this time, Keith oversaw key teams in preparation for argenx’s first product launch, including sales, marketing, market access and reimbursement, business operations, patient services and medical affairs. In 2023, he transitioned from this role to serve as a strategic commercial advisor to the board of directors of argenx.
Prior to argenx, Keith served as senior vice president of North American operations for Alexion Pharmaceuticals, Inc., where he managed a team of several hundred people in the U.S. and Canada. Additionally, within his tenure at Alexion, he served as vice president and managing director of Alexion UK, overseeing all aspects of Alexion’s UK business. Previously, he held various positions of increasing responsibility within Roche, Amgen, and Eisai Co., Ltd., over a span of 20 years.
Keith currently serves on the board of directors of Neurogene Inc. and TScan Therapeutics, Inc. He holds a Bachelor of Science in marketing from Florida State University.
What is Keith Woods' net worth?
The estimated net worth of Keith Woods is at least $26.23 million as of January 13th, 2026. Woods owns 583,254 shares of Scholar Rock stock worth more than $26,228,932 as of January 19th. This net worth approximation does not reflect any other assets that Woods may own. Learn More about Keith Woods' net worth.
How do I contact Keith Woods?
Has Keith Woods been buying or selling shares of Scholar Rock?
Over the course of the past ninety days, Keith Woods has sold $715,054.20 in Scholar Rock stock. Most recently, Keith Woods sold 16,746 shares of the business's stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $42.70, for a transaction totalling $715,054.20. Following the completion of the sale, the chief operating officer now directly owns 583,254 shares of the company's stock, valued at $24,904,945.80. Learn More on Keith Woods' trading history.
Who are Scholar Rock's active insiders?
Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Kristina Burow (Director), Jeffrey Flier (Director), Michael Gilman (Director), David Hallal (CEO), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), Joshua Reed (Director), Tracey Sacco (Chief Commercial Officer), Vikas Sinha (CFO), Akshay Vaishnaw (President, R&D), Keith Woods (COO), and Keith Woods (COO). Learn More on Scholar Rock's active insiders.
Are insiders buying or selling shares of Scholar Rock?
In the last year, Scholar Rock insiders bought shares 3 times. They purchased a total of 530,038 shares worth more than $19,988,928.11. In the last year, insiders at the sold shares 27 times. They sold a total of 618,391 shares worth more than $24,126,909.07. The most recent insider tranaction occured on January, 14th when insider Mo Qatanani sold 13,112 shares worth more than $592,662.40. Insiders at Scholar Rock own 13.3% of the company.
Learn More about insider trades at Scholar Rock. Information on this page was last updated on 1/14/2026.
